Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer
-
Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years
-
Lynparza improved the time women lived without disease progression to 22 months in the broad population and to 37 months in HRD-positive patients as 1st-line maintenance treatment with bevacizumab for newly-diagnosed advanced ovarian cancer
-
AstraZeneca to present next wave of science in respiratory disease at ERS International Congress
-
Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes
-
AstraZeneca amends collaboration with Ironwood for Linzess in China
-
AstraZeneca redefines cancer treatment with practice-changing data at ESMO 2019
-
FDA grants Fast Track designation for Farxiga in heart failure
-
Imfinzi is first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer
-
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
